GO:2000261 negative regulation of blood coagulation, common pathway: Anticoagulant Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000261 describes any process that stops, prevents, or reduces the frequency, rate, or extent of the common pathway of blood coagulation.
• The common pathway is the final convergence point of the coagulation cascade, where factor Xa, factor Va, calcium, and phospholipids assemble into the prothrombinase complex to generate thrombin.
• Negative regulation of this pathway is dominated by the protein C anticoagulant system, which proteolytically inactivates factors Va and VIIIa.
• Key molecular players include PROC (protein C), PROS1 (protein S), THBD (thrombomodulin), SERPINC1 (antithrombin), and the endothelial protein C receptor (PROCR).
• Dysregulation of this process contributes to thrombophilia, disseminated intravascular coagulation, and sepsis-associated coagulopathy.
• CRISPR-based knockout, point mutation, and knock-in models are powerful tools to dissect the causal roles of individual anticoagulant genes in the common pathway.
Description
The common pathway of blood coagulation is the terminal segment of the coagulation cascade, in which activated factor X (FXa) and its cofactor factor Va (FVa) assemble on a phospholipid surface to convert prothrombin to thrombin. Because thrombin generation is the central event that leads to fibrin formation and platelet activation, the common pathway is a critical control point for preventing excessive or misplaced clotting. GO:2000261, negative regulation of blood coagulation, common pathway, captures the biological processes that restrain this terminal cascade. Understanding these inhibitory mechanisms is essential for researchers studying hemostatic balance, thrombosis, and inflammation. The protein C anticoagulant pathway is the best-characterized negative regulator of the common pathway. In this system, thrombin bound to thrombomodulin activates protein C, which then cleaves and inactivates FVa and FVIIIa, thereby dampening thrombin generation. This article integrates the QuickGO definition of GO:2000261 with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links, and experimental models relevant to this term.
negative regulation of blood coagulation, common pathway At A Glance
| GO ID | GO:2000261 |
|---|---|
| GO term | negative regulation of blood coagulation, common pathway |
| Ontology | biological_process |
| Synonym | none |
| Major function | Suppression of the terminal common pathway of blood coagulation, primarily through anticoagulant systems such as the protein C pathway |
| Key regulators | Protein C (PROC), protein S (PROS1), thrombomodulin (THBD), endothelial protein C receptor (PROCR), antithrombin (SERPINC1) |
| Target factors | Activated factor V (FVa) and activated factor VIII (FVIIIa) |
| Physiological outcome | Reduced thrombin generation and fibrin formation |
| Disease relevance | Thrombophilia, disseminated intravascular coagulation, sepsis-associated coagulopathy |
What Is GO:2000261?
GO:2000261 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of blood coagulation via the common pathway. In practice, this includes molecular events such as the proteolytic inactivation of coagulation factors, the action of stoichiometric inhibitors, and the modulation of cofactor availability that collectively suppress the terminal steps of the coagulation cascade.
Why Is negative regulation of blood coagulation, common pathway Important in Cell Biology?
GO:2000261 is important because the common pathway is the final common route for thrombin generation, and its negative regulation prevents pathological thrombosis while maintaining hemostasis. Defects in this regulatory process are directly linked to thrombotic disorders, and understanding it informs the development of anticoagulant therapies and diagnostic strategies.
• Prevents excessive thrombin generation and disseminated intravascular coagulation.
• Maintains blood fluidity under normal physiological conditions.
• Dysregulation is associated with inherited and acquired thrombophilia.
• Provides targets for anticoagulant drug development, such as activated protein C.
• Modulates inflammation and sepsis outcomes through crosstalk with coagulation.
• Essential for understanding the balance between hemostasis and thrombosis.
• Guides interpretation of genetic variants in PROC, PROS1, and THBD.
• Informs experimental models of coagulopathy and thrombosis.
What Happens During negative regulation of blood coagulation, common pathway?
Initiation of the Protein C Anticoagulant Pathway
In simple terms: Thrombin, the key clotting enzyme, can switch from being procoagulant to anticoagulant when it binds to thrombomodulin on endothelial cells.
The negative regulation of the common pathway begins when thrombin, generated via the common pathway, binds to thrombomodulin (THBD) on the endothelial surface. This binding alters thrombin's substrate specificity, shifting it from fibrinogen cleavage toward activation of protein C (PROC). The endothelial protein C receptor (PROCR) further enhances this activation by presenting protein C to the thrombin-thrombomodulin complex. This step is a critical checkpoint that links thrombin generation to its own downregulation.
Activation of Protein C and Formation of Activated Protein C
In simple terms: Protein C is converted into its active form, activated protein C (APC), which acts as a molecular scissors that cuts other clotting factors.
Once bound to the thrombin-thrombomodulin complex, protein C is cleaved at a specific activation peptide, releasing activated protein C (APC). APC is a serine protease that requires calcium ions and a phospholipid membrane surface for optimal activity. Protein S (PROS1) serves as a cofactor for APC, enhancing its binding to negatively charged phospholipid membranes and its ability to inactivate target factors.
Proteolytic Inactivation of Factor Va and Factor VIIIa
In simple terms: APC cuts and destroys two key accelerator proteins, factor Va and factor VIIIa, which are needed for the common pathway to proceed efficiently.
APC exerts its anticoagulant effect by proteolytically cleaving activated factor V (FVa) and activated factor VIII (FVIIIa). FVa is a cofactor for the prothrombinase complex, and FVIIIa is a cofactor for the tenase complex; their inactivation dramatically reduces thrombin generation. The cleavage sites in FVa and FVIIIa have been mapped, and mutations at these sites can confer resistance to APC, a common risk factor for thrombosis.
Stoichiometric Inhibition by Serpins
In simple terms: Other inhibitors, like antithrombin, act as molecular traps that bind and neutralize thrombin and factor Xa directly.
In addition to the protein C pathway, serine protease inhibitors (serpins) such as antithrombin (SERPINC1) provide a stoichiometric brake on the common pathway. Antithrombin forms irreversible complexes with thrombin and factor Xa, and its activity is greatly enhanced by heparin-like glycosaminoglycans. This mechanism ensures that any thrombin or FXa that escapes the protein C system is rapidly neutralized.
Key Genes Involved in GO:2000261 negative regulation of blood coagulation, common pathway
The following genes encode the major proteins that mediate or regulate the negative regulation of the common pathway of blood coagulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PROC | Encodes protein C, the zymogen of activated protein C (APC) | Mutations cause hereditary protein C deficiency and thrombophilia |
| PROS1 | Encodes protein S, a cofactor for APC | Deficiency is linked to venous thrombosis |
| THBD | Encodes thrombomodulin, the endothelial receptor that activates protein C | Polymorphisms affect thrombosis risk and sepsis outcomes |
| PROCR | Encodes endothelial protein C receptor, enhances protein C activation | Modulates APC generation and inflammation |
| SERPINC1 | Encodes antithrombin, a direct inhibitor of thrombin and FXa | Deficiency causes severe thrombophilia |
| F5 | Encodes factor V; APC cleaves and inactivates FVa | Factor V Leiden mutation causes APC resistance |
| F8 | Encodes factor VIII; APC cleaves and inactivates FVIIIa | Mutations affect hemophilia A and thrombosis |
| F2 | Encodes prothrombin; thrombin is the central enzyme of the common pathway | Prothrombin G20210A variant increases thrombosis risk |
| F10 | Encodes factor X; FXa is the protease of the prothrombinase complex | Target for direct oral anticoagulants |
| F9 | Encodes factor IX; contributes to tenase complex upstream of common pathway | Deficiency causes hemophilia B |
| VWF | Encodes von Willebrand factor; modulates platelet adhesion and coagulation | Defects cause von Willebrand disease |
| PLG | Encodes plasminogen; fibrinolysis counterbalances coagulation | Deficiency linked to thrombosis |
| SERPINE1 | Encodes plasminogen activator inhibitor-1; regulates fibrinolysis | Elevated levels associated with thrombotic risk |
| FGA | Encodes fibrinogen alpha chain; substrate for thrombin | Mutations cause dysfibrinogenemia |
| FGB | Encodes fibrinogen beta chain | Variants affect fibrin clot structure |
| FGG | Encodes fibrinogen gamma chain | Mutations linked to amyloidosis and thrombosis |
| ANXA5 | Encodes annexin A5; binds phospholipids and inhibits prothrombinase | Polymorphisms associated with recurrent pregnancy loss |
How Is negative regulation of blood coagulation, common pathway Regulated?
The negative regulation of the common pathway is itself tightly regulated at multiple levels. Protein C activation is modulated by the availability of thrombomodulin and PROCR on endothelial cells, which can be downregulated by inflammatory cytokines. Protein S cofactor activity is regulated by binding to C4b-binding protein, which reduces its effective concentration. Antithrombin activity is potentiated by heparan sulfate proteoglycans on the vessel wall. Additionally, the fibrinolytic system, through plasminogen activators and inhibitors, provides a parallel regulatory layer that dissolves fibrin once it has formed.
negative regulation of blood coagulation, common pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PROC | Hereditary protein C deficiency, thrombophilia | Knockout mouse or knock-in of patient variants |
| F5 | Factor V Leiden, APC resistance, venous thrombosis | Point mutation knock-in (F5 R506Q) in mice |
| SERPINC1 | Antithrombin deficiency, severe thrombophilia | Liver-specific knockout or overexpression |
| THBD | Sepsis-associated coagulopathy, thrombosis | Endothelial-specific knockout or point mutation |
| PROCR | Modulates inflammation and APC generation | Knockout or tagged knock-in for imaging |
Thrombophilia and Venous Thromboembolism
Defects in the negative regulation of the common pathway are major risk factors for venous thromboembolism. Heterozygous protein C deficiency, protein S deficiency, and antithrombin deficiency are established inherited thrombophilias. The factor V Leiden mutation (F5 R506Q) renders FVa resistant to APC cleavage, leading to a prothrombotic state. These conditions highlight the clinical importance of GO:2000261 in maintaining hemostatic balance.
Sepsis-Associated Disseminated Intravascular Coagulation
During severe infection, inflammatory mediators downregulate thrombomodulin and PROCR, impairing the protein C pathway and tipping the balance toward coagulation. This contributes to disseminated intravascular coagulation (DIC), a life-threatening condition characterized by widespread microthrombosis and bleeding. The pathophysiology of bacteremia and sepsis directly involves dysregulation of the common pathway's negative regulation.
Diabetic Foot Ulcers and Impaired Healing
Chronic wounds such as diabetic foot ulcers exhibit altered coagulation and immune responses. Although direct evidence for GO:2000261 in this context is limited, the interplay between coagulation and inflammation suggests that impaired negative regulation may contribute to the persistent inflammatory state observed in non-healing wounds.
From negative regulation of blood coagulation, common pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PROC increase thrombosis risk? | PROC knockout mouse or CRISPR knockout cell line |
| Does the F5 R506Q mutation cause APC resistance? | Point mutation knock-in in mice or human cell lines |
| How does THBD downregulation affect common pathway regulation? | Endothelial-specific THBD knockout or knockdown |
| Can overexpression of PROS1 enhance anticoagulation? | PROS1 overexpression lentiviral or transgenic model |
| Where is PROCR localized on endothelial cells? | Tagged knock-in with fluorescent protein |
| What is the effect of SERPINC1 deficiency on thrombin generation? | SERPINC1 knockout hepatocyte cell line |
How to Study the negative regulation of blood coagulation, common pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thrombin generation assay | Kinetics of thrombin formation | Diagnosis of APC resistance and thrombophilia |
| Next-generation sequencing | Genetic variants in anticoagulant genes | Identification of PROC, PROS1, SERPINC1 mutations |
| Western blotting | Protein levels and cleavage fragments | Detection of FVa and FVIIIa inactivation |
| Activity-based protease assay | APC enzymatic activity | Functional characterization of APC variants |
| Immunofluorescence microscopy | Subcellular localization of pathway components | Visualization of THBD and PROCR on endothelium |
| Label-free proteomics | Global protein expression changes | Discovery of novel regulators in disease models |
| CRISPR screening | Gene essentiality and pathway modifiers | Identification of novel negative regulators |
| Single-cell RNA-seq | Cell-type-specific expression profiles | Mapping anticoagulant gene expression in tissues |
Thrombin Generation Assays
Thrombin generation assays (TGAs) measure the kinetics of thrombin production in plasma or cell-based systems and are widely used to assess the functional impact of negative regulators of the common pathway. These assays can detect APC resistance and quantify the effect of genetic variants in PROC, PROS1, or F5.
Genetic and Genomic Approaches
Next-generation sequencing and targeted genotyping are used to identify variants in anticoagulant genes such as PROC, PROS1, and SERPINC1. Transcriptomic profiling can reveal changes in gene expression associated with coagulation dysregulation in disease states.
Proteomic and Functional Protease Assays
Label-free proteomics and activity-based assays can quantify protein levels and cleavage events of FVa and FVIIIa by APC. These methods help dissect the molecular mechanisms of negative regulation at the protein level.
Cell-Based Models and Imaging
Endothelial cell culture systems and fluorescence microscopy are used to study the assembly of the protein C pathway components on cell surfaces. Live-cell imaging of tagged PROCR or THBD provides spatial and temporal insights into activation of protein C.
How CRISPR Can Be Used to Study GO:2000261 negative regulation of blood coagulation, common pathway
Knockout
CRISPR knockout of PROC, PROS1, THBD, or SERPINC1 in cell lines or animal models can abolish negative regulation of the common pathway, leading to a prothrombotic phenotype. These models are essential for establishing causality and for testing anticoagulant therapies.
Point Mutation
Introducing precise point mutations such as F5 R506Q (Factor V Leiden) or PROC missense variants via CRISPR base editing or homology-directed repair allows researchers to study the functional consequences of specific patient alleles. Such models mimic human thrombophilia and can be used for drug screening.
Knock-in
Knock-in of tagged versions of PROCR or THBD (e.g., fluorescent or epitope tags) enables real-time imaging and biochemical isolation of these proteins in their native context. This approach provides insights into the spatiotemporal dynamics of protein C activation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of PROS1 or PROC can enhance the negative regulation of the common pathway, offering a strategy to counteract thrombosis. Overexpression models are useful for dose-response studies and for validating therapeutic targets.
How EDITGENE Supports negative regulation of blood coagulation, common pathway Research
Researchers studying negative regulation of blood coagulation, common pathway-related genes often need to determine whether a candidate gene is causally involved in suppressing thrombin generation or whether its association is merely correlative. This requires precise, reproducible genetic models that can isolate the contribution of individual anticoagulant factors. EDITGENE provides end-to-end CRISPR services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of blood coagulation, common pathway research.
Frequently Asked Questions About negative regulation of blood coagulation, common pathway
What is GO:2000261?
GO:2000261 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of blood coagulation via the common pathway.
What genes are involved in negative regulation of blood coagulation, common pathway?
Key genes include PROC, PROS1, THBD, PROCR, and SERPINC1, which encode proteins of the protein C anticoagulant system and antithrombin.
How does the protein C pathway inhibit blood coagulation?
Thrombin bound to thrombomodulin activates protein C; activated protein C then cleaves and inactivates factors Va and VIIIa, reducing thrombin generation.
What diseases are associated with defects in this pathway?
Defects cause thrombophilia, venous thromboembolism, and sepsis-associated disseminated intravascular coagulation.
What is the role of factor V Leiden in this process?
The factor V Leiden mutation (F5 R506Q) makes factor Va resistant to cleavage by activated protein C, impairing negative regulation and increasing thrombosis risk.
How can CRISPR be used to study GO:2000261?
CRISPR knockout, point mutation, and knock-in models allow researchers to test the causal role of individual anticoagulant genes in the common pathway.
What experimental methods measure negative regulation of the common pathway?
Thrombin generation assays, APC resistance tests, and genetic sequencing are commonly used to assess this process.
Is antithrombin part of the negative regulation of the common pathway?
Yes, antithrombin directly inhibits thrombin and factor Xa, providing a stoichiometric brake on the common pathway.
What cell types are most relevant for studying this process?
Endothelial cells are central because they express thrombomodulin and PROCR, which are required for protein C activation.
Can overexpression of protein S enhance anticoagulation?
Yes, protein S is a cofactor for activated protein C, and increasing its levels can enhance the inactivation of factors Va and VIIIa.
Conclusion
GO:2000261, negative regulation of blood coagulation, common pathway, is a critical biological process that prevents excessive thrombin generation and thrombosis. The protein C anticoagulant system, along with antithrombin, provides the main inhibitory mechanisms, and their dysfunction is linked to thrombophilia and disseminated intravascular coagulation. CRISPR-based models are indispensable for dissecting the causal roles of individual genes in this pathway. EDITGENE offers comprehensive services to support such research, from knockout and point mutation models to library screening and bioinformatics.
References
- 1. Dahlbäck B et al.. 2005. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition.. Arterioscler Thromb Vasc Biol 25(7):1311-20 PMID: 15860736
- 2. Christodoulou CC et al.. 2023. Unraveling the transcriptomic signatures of Parkinson's disease and major depression using single-cell and bulk data.. Front Aging Neurosci 15:1273855 PMID: 38020762
- 3. Troy GC. 1988. An overview of hemostasis.. Vet Clin North Am Small Anim Pract 18(1):5-20 PMID: 3282384
- 4. McCabe WR et al.. 1983. Pathophysiology of bacteremia.. Am J Med 75(1B):7-18 PMID: 6349346
- 5. Dahlbäck B et al.. 2005. The anticoagulant protein C pathway.. FEBS Lett 579(15):3310-6 PMID: 15943976
- 6. Cheng Y et al.. 2024. Identification of potential immunologic resilience in the healing process of diabetic foot ulcers.. Int Wound J 21(3):e14465 PMID: 37926487
- 8. Panis C et al.. 2014. Label-free proteomic analysis of breast cancer molecular subtypes.. J Proteome Res 13(11):4752-72 PMID: 25221861
